Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis

Autoría

autor: James Chih-Hsin Yang, Yi-Long Wu, Jun Zhao, Jianying Zhou, Te-Chun Hsia, Shun Lu, Dong-Wan Kim, Chong-Kin Liam, Ross A Soo